Find Information About:

Drugs & Supplements

Get information and reviews on prescription drugs, over-the-counter medications, vitamins, and supplements. Search by name or medical condition.

Pill Identifier
WebMD

Pill Identifier

Having trouble identifying your pills?

Enter the shape, color, or imprint of your prescription or OTC drug. Our pill identification tool will display pictures that you can compare to your pill.

Get Started
My Medicine
WebMD

My Medicine

Save your medicine, check interactions, sign up for FDA alerts, create family profiles and more.

Get Started

WebMD Health Experts and Community

Talk to health experts and other people like you in WebMD's Communities. It's a safe forum where you can create or participate in support groups and discussions about health topics that interest you.

  • Second Opinion
    WebMD

    Second Opinion

    Read expert perspectives on popular health topics.

  • Community
    WebMD

    Community

    Connect with people like you, and get expert guidance on living a healthy life.

Got a health question? Get answers provided by leading organizations, doctors, and experts.

Get Answers

Sign up to receive WebMD's award-winning content delivered to your inbox.

Sign Up

Macular Degeneration Health Center

Font Size
A
A
A

Avastin as Good as Lucentis for AMD Treatment

Study: Less-Expensive Avastin Treats Age-Related Macular Degeneration as Well as Lucentis

Lucentis vs. Avastin for AMD

Unlike earlier treatments, which slowed the rate at which patients went blind, both Lucentis and Avastin stop vision loss for nearly all patients and actually improve many patients' vision.

"On all measures of visual acuity, the two drugs were virtually identical," study leader Daniel F. Martin, MD, chairman of the Cole Eye Institute at the Cleveland Clinic, said at a news teleconference.

"This study is unequivocal in saying there is minimal and likely no difference between as-needed and monthly treatment," Paul A. Sieving, MD, PhD, director of the National Eye Institute, said at the news conference.

Moreover, the study found that neither Avastin nor Lucentis increased patients' risk of stroke, heart attack, or death -- side effects seen in cancer patients given vastly higher doses of Avastin.

So why would any doctor give a patient $2,000-a-dose Lucentis when $50-a-dose Avastin works just as well?

"When one is selecting drugs for an individual patient, cost is one of many factors, not the only one," Martin said. "In our study we describe the average patient. ... We clearly show equivalence between the two drugs, but that does not mean there are not subsets of patients who might respond better to one drug over another. At the end of the day it is a choice between the doctor and the patient."

Genentech had no role in funding, performing, or interpreting the study. Study drugs were paid for by Medicare and by the National Institutes of Health.

The Avastin/Lucentis study, called the CATT study, was published in the April 28 early online edition of the New England Journal of Medicine.

1 | 2

Today on WebMD

What Is Macular Degeneration
Article
human eye
Article
 
What Someone With Macular Degeneration Sees
Tool
picture of the eyes
Image Collection
 

eye exam
Article
Treatments For Macular Degeneration
Article
 
the aging eye
Video
senior woman wearing glasses
Article
 

WebMD Special Sections